CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Guggenheim Genomic Medicines and Rare Disease Days in New York City on Monday, April 3, 2023 at 2:10 p.m. ET.
A live webcast of this presentation will be available on the Investor Relations page of the Wave Life Sciences corporate website at http://ir.wavelifesciences.com. Replay of this presentation will be archived and available on the site for a limited time following the event.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.
Investor Contact:
Kate Rausch
617-949-4827
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Alicia Suter
617-949-4817
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$4.66 |
Daily Change: | -0.08 -1.69 |
Daily Volume: | 396,682 |
Market Cap: | US$569.820M |
March 06, 2024 February 27, 2024 December 15, 2023 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB